If you cannot see this email please follow this link.
Newsletter Regulatory Affairs
Your monthly regulatory affairs update
Dear Sir or Madam,

Welcome to the May 2023 issue of the regulatory affairs newsletter.

Today you will receive an overview of regulatory issues of the last few weeks as well as a summary of the online conference on the upcoming EU legislation (pharmaceutical legislation and EU-HTA).
Editorial
News from the EU Commission
News from the ICH
News from EMA
News from BfArM and PEI
Monthly reports
EU Legislation 2023: Update on Orphans, Paediatrics, EU-HTA & Pharma Legislation

Author: Dr Henriette Wolf-Klein, FORUM Institut für Management GmbH

On 28 April 2023, the online conference on the upcoming EU legislation took place. The focus was on the Pharmaceutical Legislation with the Draft-Regulation 2023/0131 and the Draft-Directive 2023/0132 as well as the upcoming EU-HTA procedure ... more
News from the EU Commission
HERA plays an important role in bringing medical countermeasures to the market in the fight against Antimicrobial Resistance (AMR), as outlined in a new study published by HaDEA.
Details


The eHealth Network has published the guideline on the exchange of health data under Cross-Border Directive 2011/24/EU - Patient Summary.
Details


News from the ICH
The ICH S12 Guideline on nonclinical biodistribution considerations for gene therapy products will come into effect on 30 September 2023.
Details


The ICH M7(R2) Guideline on the "Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk" and the accompanying M7(R2) Addendum "Application of the Principles of the ICH M7 Guideline to Calculation of Compound-Specific Acceptable Intakes" have reached Step 4 of the ICH Process on 3 April 2023.
Details


PharmaFORUM Webcast International - More information >>


News from EMA
The public consultation of the concept paper "on revision of the Guideline on clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome" ends on 31 July 2023.
Details


EMA publishes a reflection paper to reflect the current thinking of EMA´s CHMP on single-arm trials (SATs) that are submitted as pivotal evidence for establishing efficacy in a marketing authorisation application.
Details


PLM: EMA published the revised “Human Variations electronic Application Form (eAF) timeline.
Details

On 4 October Karl-Heinz Loebel and Dr Georg Neuwirther address these topics in the German speaking course "Product Lifecycle Management (PLM) Portal in der praktischen Nutzung".
Details



News from BfArM and PEI
The PEI informs "How the safety of medicinal products is monitored - An introduction".
Details


PharmaFORUM Webcast Biologics - More information >>


Monthly reports
PRAC:
Details


CHMP:
Details


CMDh:
Details


CVMP:
Details

Kind regards,

Dr Rebekka Bitsch
Your contact for
Regulatory Affairs (Human)
+49 6221 500-565
Dr C. Michaela Gottwald
Your contact for
Regulatory Affairs (Veterinary)
+49 6221 500-610
Dr Birgit Wessels
Your contact for
Quality, Safety, CMC
+49 6221 500-652


TO UNSUBSCRIBE:
If you do not want to receive this information in future, you can unsubscribe here!
FORUM · Institut für Management GmbH · Vangerowstr. 18 · 69115 Heidelberg · Germany
Fon +49 6221 500-500 · Fax +49 6221 500-555 · service@forum-institut.de · www.forum-institut.com
Copyright 2023 FORUM · Institut für Management GmbH
Imprint, privacy policy, terms and conditions